Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Eva Drapalova, Vendula Belackova, Dina Calado, Alex Van Dongen, Iva Paneva, Raimondo Pavarin, Edoardo Polidori & Jean-Paul Grund. (2019) Early Identification of Locally Emerging Trends in Psychoactive Substance Use – Experience and Best Practice in Four European Localities. Substance Use & Misuse 54:10, pages 1633-1645.
Read now
Read now
James
Allen Wilcox & Aidee
Herrera Wilcox. (2009) Movement Disorders and MDMA Abuse. Journal of Psychoactive Drugs 41:2, pages 203-204.
Read now
Read now
Loes Keijsers, Matthijs G. Bossong & Arend
Jan Waarlo. (2008) Participatory evaluation of a Dutch warning campaign for substance-users. Health, Risk & Society 10:3, pages 283-295.
Read now
Read now
Rif S. El-Mallakh & Henry David Abraham. (2007) MDMA (Ecstasy). Annals of Clinical Psychiatry 19:1, pages 45-52.
Read now
Read now
Alison Ritter, Alison Ritter, Jacqui Cameron, Alison Ritter & Jacqui Cameron. (2006) A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs. Drug and Alcohol Review 25:6, pages 611-624.
Read now
Read now
Articles from other publishers (39)
Samantha Davis, Bruce Wallace, Thea Van Roode & Dennis Hore. (2022) Substance Use Stigma and Community Drug Checking: A Qualitative Study Examining Barriers and Possible Responses. International Journal of Environmental Research and Public Health 19:23, pages 15978.
Crossref
Crossref
Thomas F. Martinelli, Freya Vander Laenen, Gera E. Nagelhout & Dike H. van de Mheen. (2022) Addiction and Recovery in Dutch Governmental and Practice-Level Drug Policy: What’s the Problem Represented to be?. Journal of Drug Issues 52:4, pages 547-567.
Crossref
Crossref
Nazlee Maghsoudi, Justine Tanguay, Kristy Scarfone, Indhu Rammohan, Carolyn Ziegler, Dan Werb & Ayden I. Scheim. (2021) Drug checking services for people who use drugs: a systematic review. Addiction 117:3, pages 532-544.
Crossref
Crossref
Moritz Losacker, Siegfried Zörntlein, Bernd Schwarze, Svenja Staudt, Jörg Röhrich & Cornelius Hess. (2021)
Determination of the enantiomeric composition of amphetamine, methamphetamine and 3,4‐methylendioxy‐
N
‐methylamphetamine (MDMA) in seized street drug samples from southern Germany
. Drug Testing and Analysis 14:3, pages 557-566.
Crossref
Crossref
N. Maghsoudi, K. McDonald, C. Stefan, D. R. Beriault, K. Mason, L. Barnaby, J. Altenberg, R. D. MacDonald, J. Caldwell, R. Nisenbaum, P. Leece, T. M. Watson, K. W. Tupper, L. Kufner, A. I. Scheim & D. Werb. (2020) Evaluating networked drug checking services in Toronto, Ontario: study protocol and rationale. Harm Reduction Journal 17:1.
Crossref
Crossref
Lisa Benaglia, Robin Udrisard, Anne Bannwarth, Aline Gibson, Frederic Béen, Foon Yin Lai, Pierre Esseiva & Olivier Delémont. (2020) Testing wastewater from a music festival in Switzerland to assess illicit drug use. Forensic Science International 309, pages 110148.
Crossref
Crossref
Yoshimi Peck, Alan R. Clough, Peter N. Culshaw & Michael J. Liddell. (2019) Multi-drug cocktails: Impurities in commonly used illicit drugs seized by police in Queensland, Australia. Drug and Alcohol Dependence 201, pages 49-57.
Crossref
Crossref
Fiona Catherine Measham. (2019) Drug safety testing, disposals and dealing in an English field: Exploring the operational and behavioural outcomes of the UK’s first onsite ‘drug checking’ service. International Journal of Drug Policy 67, pages 102-107.
Crossref
Crossref
Andrew Groves. (2018) ‘Worth the test?’ Pragmatism, pill testing and drug policy in Australia. Harm Reduction Journal 15:1.
Crossref
Crossref
Matthew K. Laing, Kenneth W. Tupper & Nadia Fairbairn. (2018) Drug checking as a potential strategic overdose response in the fentanyl era. International Journal of Drug Policy 62, pages 59-66.
Crossref
Crossref
Sascha B. Thal & Miriam J. J. Lommen. (2018) Current Perspective on MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder. Journal of Contemporary Psychotherapy 48:2, pages 99-108.
Crossref
Crossref
Tibor M. Brunt, Constanze Nagy, Alexander Bücheli, Daniel Martins, Miren Ugarte, Cécile Beduwe & Mireia Ventura Vilamala. (2017) Drug testing in Europe: monitoring results of the Trans European Drug Information (TEDI) project. Drug Testing and Analysis 9:2, pages 188-198.
Crossref
Crossref
Kane Race, Toby Lea, Dean Murphy & Kiran Pienaar. (2017) The future of drugs: recreational drug use and sexual health among gay and other men who have sex with men. Sexual Health 14:1, pages 42.
Crossref
Crossref
Rif S. El‐Mallakh, John H. Halpern & Henry David Abraham. 2015. Psychiatry. Psychiatry
1480
1506
.
Matthew G. Kirkpatrick, Matthew J. Baggott, John E. Mendelson, Gantt P. Galloway, Matthias E. Liechti, Cédric M. Hysek & Harriet de Wit. (2014) MDMA effects consistent across laboratories. Psychopharmacology 231:19, pages 3899-3905.
Crossref
Crossref
Stephen Wakeman. (2013)
‘No one wins. One side just loses more slowly’:
The Wire
and drug policy
. Theoretical Criminology 18:2, pages 224-240.
Crossref
Crossref
Marie Ouellet & Carlo Morselli. (2013) Precursors and Prices. Journal of Drug Issues 44:1, pages 37-55.
Crossref
Crossref
Andrew C. Parrott. (2013) Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research. Human Psychopharmacology: Clinical and Experimental 28:4, pages 289-307.
Crossref
Crossref
Márcia Carvalho, Helena Carmo, Vera Marisa Costa, João Paulo Capela, Helena Pontes, Fernando Remião, Félix Carvalho & Maria de Lourdes Bastos. (2012) Toxicity of amphetamines: an update. Archives of Toxicology 86:8, pages 1167-1231.
Crossref
Crossref
Tibor M. Brunt, Raymond J.M. Niesink & Wim van den Brink. (2012) Impact of a transient instability of the ecstasy market on health concerns and drug use patterns in The Netherlands. International Journal of Drug Policy 23:2, pages 134-140.
Crossref
Crossref
Tibor M. Brunt & Raymond J.M. Niesink. (2011) The Drug Information and Monitoring System (DIMS) in the Netherlands: Implementation, results, and international comparison. Drug Testing and Analysis 3:9, pages 621-634.
Crossref
Crossref
Claire Cole, Lisa Jones, Jim McVeigh, Andrew Kicman, Qutub Syed & Mark Bellis. (2011) Adulterants in illicit drugs: a review of empirical evidence. Drug Testing and Analysis 3:2, pages 89-96.
Crossref
Crossref
MG BossongTM Brunt, JP Van Dijk, SM Rigter, J. Hoek, HMJ Goldschmidt & RJM Niesink. (2009) mCPP: an undesired addition to the ecstasy market. Journal of Psychopharmacology 24:9, pages 1395-1401.
Crossref
Crossref
Alison Ritter. (2010) Illicit drugs policy through the lens of regulation. International Journal of Drug Policy 21:4, pages 265-270.
Crossref
Crossref
Neeltje Vogels, Tibor M. Brunt, Sander Rigter, Peter Van Dijk, Hylke Vervaeke & Raymond J. M. Niesink. (2009) Content of ecstasy in the Netherlands: 1993–2008. Addiction 104:12, pages 2057-2066.
Crossref
Crossref
K Allott, BJ Canny, JH Broadbear, NK Stepto, B Murphy & J Redman. (2008) Neuroendocrine and subjective responses to pharmacological challenge with citalopram: a controlled study in male and female ecstasy/MDMA users. Journal of Psychopharmacology 23:7, pages 759-774.
Crossref
Crossref
Tibor M. Brunt, Sander Rigter, Jani Hoek, Neeltje Vogels, Peter Van Dijk & Raymond J. M. Niesink. (2009) An analysis of cocaine powder in the Netherlands: content and health hazards due to adulterants. Addiction 104:5, pages 798-805.
Crossref
Crossref
Jennifer Johnston, Monica J. Barratt, Craig L. Fry, Stuart Kinner, Mark Stoové, Louisa Degenhardt, Jessica George, Rebecca Jenkinson, Matthew Dunn & Raimondo Bruno. (2006) A survey of regular ecstasy users’ knowledge and practices around determining pill content and purity: Implications for policy and practice. International Journal of Drug Policy 17:6, pages 464-472.
Crossref
Crossref
Ryan M. Smith, Madalina Tivarus, Heather L. Campbell, Ashleigh Hillier & David Q. Beversdorf. (2006) Apparent Transient Effects of Recent ???Ecstasy??? Use on Cognitive Performance and Extrapyramidal Signs in Human Subjects. Cognitive and Behavioral Neurology 19:3, pages 157-164.
Crossref
Crossref
Emily E. Tanner-Smith. (2006) Pharmacological content of tablets sold as “ecstasy”: Results from an online testing service. Drug and Alcohol Dependence 83:3, pages 247-254.
Crossref
Crossref
Andy C. Parrott. (2016) MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. Journal of Psychopharmacology 20:2, pages 147-163.
Crossref
Crossref
Claire E. Sterk, Katherine P. Theall & Kirk W. Elifson. (2016) Young Adult Ecstasy use Patterns: Quantities and Combinations. Journal of Drug Issues 36:1, pages 201-228.
Crossref
Crossref
M. Bossong, J. Van Dijk & R. Niesink. (2006) Methylone and mCPP, two new drugs of abuse?. Addiction Biology 10:4, pages 321-323.
Crossref
Crossref
A. C. Parrott. (2016) Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. Journal of Psychopharmacology 19:1, pages 71-83.
Crossref
Crossref
Mikko Salasuo & Pauliina Seppälä. (2016) Drug Use within the Finnish Club Culture as Marks of Distinction. Contemporary Drug Problems 31:2, pages 213-229.
Crossref
Crossref
Andrew B Scholey, Andrew C Parrott, Tom Buchanan, Thomas M Heffernan, Jonathan Ling & Jacqui Rodgers. (2004) Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: A WWW study. Addictive Behaviors 29:4, pages 743-752.
Crossref
Crossref
F. Schifano, A. Oyefeso, J. Corkery, K. Cobain, R. Jambert‐Gray, G. Martinotti & A. H. Ghodse. (2003) Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996–2002. Human Psychopharmacology: Clinical and Experimental 18:7, pages 519-524.
Crossref
Crossref
H. C. Fox & A. C. Parrott. (2016) Selective Neurocognitive Deficits Associated with Multiple Doses of Ecstasy/MDMA: A Reply to Cole. Journal of Psychopharmacology 17:2, pages 242-244.
Crossref
Crossref
A. C. Parrott. (2001) Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Human Psychopharmacology: Clinical and Experimental 16:8, pages 557-577.
Crossref
Crossref